Novo Nordisk A/S $NVO Shares Bought by Markel Group Inc.

Markel Group Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,368,649 shares of the company’s stock after buying an additional 110,061 shares during the quarter. Markel Group Inc. owned about 0.05% of Novo Nordisk A/S worth $131,436,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its position in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the period. NewSquare Capital LLC raised its stake in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth $37,000. Copeland Capital Management LLC grew its position in Novo Nordisk A/S by 47.3% in the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after buying an additional 186 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $63.96 on Tuesday. The business has a 50 day moving average price of $52.44 and a 200 day moving average price of $54.54. The company has a market capitalization of $285.58 billion, a P/E ratio of 18.59 and a beta of 0.66. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NVO shares. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Morgan Stanley reaffirmed an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. CICC Research began coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 target price for the company. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $57.79.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.